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This is a perspective based on the paper “Cloning of complementary DNA encoding
T cell-replacing factor and identity with B cell growth factor II,” by Kinashi et al. (1). We
have been interested in understanding the molecular basis ofT–B cell cooperation for anti-
body formation. Although many investigators had described a number of different soluble
factors that appeared to have biological relevance to T–B cell interactions, molecular basis
of such active substances remained unknown for a long period of time. In this perspective,
I will briefly summarize the history of the initial discovery of T cell-replacing factor/B cell
growth factor II that appeared to be involved in B cell growth and differentiation, and outline
the discovery and characterization of interleukin-5. Studies of interleukin-5 have provided
strong evidence that a single cytokine exerts a variety of activities on diverse target cells.
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The reciprocal relationship between antibody production and cell-
mediated immunity had been well established by 1970. Antigen
doses, forms, and routs of administration for stimulating opti-
mum antibody production to T-dependent antigens were found
to be usually accompanied by little or no delayed-type hypersen-
sitivity (DTH), and vice versa, despite the fact that both B cell
help and DTH were properties of T cells (2). Thus, one of the key
issues was how antigen-stimulated T cells regulate both humoral
and cell-mediated immune responses. The other issue was how T
cells helped B cell differentiation into antibody-secreting cells.
The articles of Rajewsky et al. (3) and Mitchison (4) described
the involvement of the cellular cooperation of carrier-specific T
cells and hapten-specific B cells for anti-hapten antibody response
to hapten-carrier conjugates. Besides the carrier specificity of
helper T cells, these cells also strictly recognized MHC class II
molecules on antigen-presenting cells. However, in some cases, the
interactions between helper T and B cells were not restricted by
MHC class II. This was explained by the possibility that both T and
B cell populations were functionally heterogeneous. The mecha-
nism underlying B cell triggering in the latter case was interpreted
to be mediated by a T cell helper effect via the release of a soluble
factor.
Evidence for the existence of such soluble factors came ini-
tially from the demonstration in the pioneering studies of Dutton
et al. (5), and Schimpl and Wecker (6), both of whom observed
that the antibody response of T cell-depleted mouse B cells to
the antigens of sheep red blood cells (SRBC) required T cell-
derived and macrophage-derived soluble factors detectable in the
supernatants obtained from short-term cultures of histoincom-
patible mouse spleen cells or Concanavalin A stimulation of mouse
spleen cells. Although various investigators had described a num-
ber of different factors that appeared to have biological relevance
to T–B cell interactions, which T cell population secreted such
active substances remained unknown. In other words, it had not
been established whether those helper T cells that released bio-
logically active mediators belonged to the same T cell population
that collaborated with B cells in direct cell-to-cell contact (cog-
nate interactions), or whether these two activities were due to two
distinct T cell subsets.
In this review, I will briefly summarize the history of the ini-
tial discovery of an activity that appeared to be involved in B cell
growth and differentiation, and outline the developments that led
to the discovery and characterization of the molecule that was
designated interleukin-5 (IL-5).
We had been interested in the adjuvant effects of Mycobacterium
tuberculosis (Tbc) on both humoral and cell-mediated immune
responses. In the early 1970s, we focused on two questions regard-
ing T and B cell cooperation for antibody production: whether a
helper T cell subset for B cell activation was also responsible for
DTH as effector T cells, and whether T cell-derived factors were
involved in B cell activation in the absence of cognate T cell help for
antibody production. At that time, the existence of T cell-derived
factors that act on B cells in an antigen-non-specific manner was
not appreciated.
Since Tbc was well known as an important ingredient of Fre-
und’s complete adjuvant, widely used to enhance antibody pro-
duction and also to augment DTH responses to a co-immunized
particular antigen, we examined tuberculin (PPD)-reactive T
cell activity in spleen cells from heat-killed Tbc-primed mice.
Helper T cell activity of Tbc-primed cells was assessed by an
adoptive cell transfer system in mice by the ability to induce
anti-2,4-dinitrophenyl (DNP) IgG antibody-secreting cells from
DNP/keyhole limpet hemocyanin (DNP-KLH)-primed mouse B
cells. As expected, anti-DNP IgG antibody production was induced
by stimulating DNP-primed B cells with DNP-PPD in the presence
of Tbc-primed cells (7). However, significant anti-DNP IgG anti-
body production was also enhanced by stimulating DNP-primed
B cells with a DNP-coupled heterologous carrier plus PPD, but
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only when Tbc-primed cells were present. Furthermore, injection
of conditioned medium of PPD-stimulated Tbc-primed cells into
recipient mice with DNP-primed B cells augmented the anti-DNP
IgG response compared with control supernatants. We tenta-
tively called the active factors produced by T cells as factors that
enhanced anti-hapten antibody production.
These findings implied that Tbc immunization of mice could
prime two types of helper T cells regarding B cell help; one trig-
gered B cells through direct cell-to-cell contact via the DNP-PPD
(cognate interaction) and the other activated their indirect inter-
action via lymphokine secretion (factor-mediated interaction).
We evaluated these possibilities by an in vitro culture system,
the results of which revealed that Tbc-primed T cells for cognate
interaction (Thc) developed as early as 7 days after Tbc-priming
and collaborated with T cell-depleted DNP-primed B cells upon
stimulation with DNP-PPD. However, Tbc-primed T cells for
factor-mediated interaction (Thf) only developed after 4 weeks of
priming and could augment the B cell response only in the pres-
ence of PPD (8). We further confirmed the existence of two distinct
types of helper T cell subpopulations, representative of Thc and
Thf, in Tbc-primed cells by establishing two distinctly function-
ing, long-term-cultured PPD-reactive helper T cell clones. Super-
natants of PPD-stimulated Tbc-primed cells enhanced anti-DNP
IgG production by DNP-primed B cells in an MHC-non-restricted
manner (9). We referred to the enhancing factor(s) as T cell-
replacing factor (TRF) because the assay systems for and biological
properties of the enhancing factor(s) thus described were similar
to those reported by Schimpl and Wecker in 1972 (6). We also
found a strain of mice, DBA/2Ha, whose DNP-primed B cells had
an X-linked B cell defect, reflected in part by the low responsiveness
to TRF, and were unable to be activated through factor-mediated
interaction, while they were good responders with Tbc-primed
T cells for cognate interaction through DNP-PPD, suggesting the
existence of two different subsets in activated B cells (9).
To obtain further insight on the molecular basis of TRF, we
took two different approaches. First, we established a monoclonal
T cell hybrid clone B151K12 by means of the fusion between Tbc-
primed BALB/c T cells and BW 5147 thymoma (10). B151K12,
which we referred to as simply B151, produced TRF-active mole-
cules continuously, without stimulation. The cell-free supernatant
of B151 could induce an anti-DNP IgG-PFC response in T cell-
depleted DNP-primed B cells from various strains of mice. It
also restored the primary anti-SRBC IgM PFC response in nu/nu
spleen cells. As B151 did not produce detectable levels of other
cytokines affecting B cell responses, we hypothesized that this
B151-derived TRF (B151-TRF) was a novel cytokine, distinct from
other cytokines. B151-TRF was able to augment B cell responses in
a totally antigen-non-specific manner and in MHC non-restricted
manner.
Secondly, we selected a particular clone of in vivo grow-
ing murine chronic B leukemia (BCL1) cells that preferentially
responded to B151-TRF and LPS, and differentiate into polyclonal
IgM-secreting cells. BCL1 cells appeared to be good target cells
for B151-TRF and thus we adopted them for further analysis of
TRF-active molecules.
Once B cells are activated, there is an early phase of proliferation
in which the responding B cell population expands many times,
and a later phase of differentiation induced by TRF in which the
already proliferating B cells move on to become Ig-secreting cells.
In the early 1980s, several interesting observations were reported
indicating that different phases of the B cell response to antigenic
stimulation are regulated by functionally and biochemically dis-
tinct factors. Howard et al. demonstrated a B cell growth factor
(BCGF) in supernatants of PMA-stimulated thymoma cells (des-
ignated EL-4) that co-stimulated purified B cells with anti-IgM
antibodies in short-term cultures, and induced polyclonal B cell
proliferation but not antibody-forming cell generation (11). The
BCGF was not mitogenic for resting B cells and interacted with
anti-IgM-activated B cells in a non-H-2-restricted manner. The
factor was distinct from T cell growth factor (IL-2) and synergized
with antigen, IL-2, and IL-2-free, BCGF-free T cell supernatants
that contained TRF to generate antibody-forming cells in cultures
of highly purified B cells (11). This was the first description of
a lymphokine activity (distinct from IL-2) that had the ability
to support B cell proliferation, and was tentatively called BCGF
(later referred to as BSF-1 and after molecular characterization,
IL-4), and the activity eluted at an apparent m.w. of 18 kDa on gel
filtration. BCGF(IL-4) was able to synergize with two additional
TRF activities to trigger B cells to Ig-secreting cells; one was a TRF-
containing cell-free supernatant from B151, and the other was a
TRF activity derived from PMA-stimulated EL-4 cells. However,
it was not clear whether these two TRF activities were identical or
distinct.
Concomitantly, Swain and Dutton reported a second BCGF
with an apparent m.w. of 50 kDa on gel filtration in a cell-free
supernatant from an IL-2-dependent T cell line (designated Den-
nert) that induced the proliferation of dextran sulfate-stimulated B
cells or BCL1 cells, whereas it did not induce anti-IgM-stimulated
B cells to proliferate (12). The 18 kDa BCGF described by Howard
et al. was designated as BCGFI and the 50 kDa BCGF as BCGFII.
Soon after that, Swain found that their BCGFII preparation was
able to induce Ig-secretion from activated B cells and that this
differentiation activity co-purified with the proliferative activity
in a variety of chromatographic separations. We demonstrated
that B151-TRF could induce not only differentiation but also the
proliferation of B cell populations that were co-stimulated with
anti-IgM antibody plus BCGFI. Swain and Dutton independently
demonstrated that B151-TRF promoted the proliferation of DXS-
stimulated B cells or BCLl cells, suggesting that B151-TRF exerted
BCGFII activity on pre-activated B cells. An important question
became whether B151 cells produced both TRF and BCGFII or
whether a B151-TRF molecule also exerted BCGFII activity.
When we started to purify TRF-active molecules to homogene-
ity, we were in the front line among TRF-hunting groups. However,
concepts of BCGFI and BCGFII for B cell growth and differenti-
ation had by this time become accepted by most workers in the
field. So, we had to clarify whether B151-TRF was identical to
either BCGFI or BCGFII. We examined the BCGFI activity of our
purified B151-TRF using anti-IgM-stimulated B cells and found
that B151-TRF did not show detectable levels of BCGFI activity.
However, we independently confirmed the activity of B151-TRF
on BCL1 cells, thereby defining that it had BCGFII activity (13).
Our strategy for identifying TRF(BCGFII) was to first
purify TRF-active molecules to homogeneity from the cell-free
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supernatant of B151, including the identification of its partial
NH2-terminal amino-acid sequence. Overall, B151-TRF was puri-
fied approximately 1,400,000-fold, and the activity could be attrib-
utable to an extremely hydrophobic glycoprotein with a molecular
mass of 40–60 kDa and a smaller mass (25–30 kDa) under reduc-
ing conditions on gel filtration. Highly purified B151-TRF also
showed BCGFII activity, whereas it did not exert detectable IL-1,
IL-2, IL-3, (BCGFI)IL-4, or IFN-γ activities. During each purifi-
cation step, the BCGFII activity could not be separated from the
TRF activity and always resided in the same fraction in which the
TRF activity was detected (13).
Although we attempted to determine the partial NH2-terminal
amino-acid sequence of purified B151-TRF several times, we were
unsuccessful. So, we immunized rats with purified B151-TRF and
their spleen cells were fused with mouse myeloma cells to gen-
erate monoclonal antibodies (mAb) reactive with B151-TRF. We
obtained two different anti-mouse TRF mAb, designated as NC17
and TB13, which neutralized the TRF and BCGFII activities of
B151-TRF, and blocked B151-TRF-induced IgM secretion and
the proliferation of BCL1, whereas they did not inhibit activi-
ties of IL-1, IL-2, IL-3, (BCGFI)IL-4, and IFN-γ (14). Immo-
bilized mAb TB13 as well as NC17 proved feasible for repro-
ducibly purifying TRF-active molecules from the conditioned
medium of B151 and PPD-stimulated Tbc-primed cells with
molecular weights of approximately 50 kDa under non-reducing
conditions (15).
To obtain concrete evidence that the molecular properties of
mouse TRF and BCGFII were in fact identical, we isolated a cDNA
encoding TRF from a 2.19 T cell line by using a pSP6K cDNA
library, in collaboration with Honjo’s group. Since structural char-
acterization was not available at that time, we felt that the best
strategy was to use an expression vector system that required only
a limited amount of mRNA. We decided to apply and construct
a new expression vector system, pSP6K containing the SP6 pro-
moter (16). With the aid of a specific RNA polymerase, the pSP6K
vector allowed the synthesis of up to a few micrograms of poly A+
RNA by in vitro transcription. This mRNA was directly injected
into Xenopus oocytes and the oocyte culture supernatants were
analyzed for their biological activities. In this way, secretory pro-
teins could be synthesized in a system that was mycoplasma-free,
free of serum proteins, and highly concentrated.
As cultured supernatants of the 2.19 T cell line exerted TRF
activity like B151-TRF, poly A+ RNA of 2.19 T cells was fraction-
ated and enriched by sucrose gradient fractionation and aliquots
of RNA were microinjected into Xenopus oocytes and the oocytes’
culture supernatants were analyzed for TRF and BCGFII activi-
ties (1). cDNA libraries from polyA+ RNA and from the mRNA
enriched by the sucrose gradient fractionation were constructed
using the pSP6K vector system. Pools that scored positive in the
biological assays were further divided into smaller pools that were
analyzed in the same manner until single cDNA clones capable of
directing the synthesis of biologically active TRF preparations were
obtained. Finally, pSP6K-mTRF was shown to encode TRF activity
(1). The isolated cDNA clones were then subjected to nucleotide
sequencing analysis.
We obtained a cDNA clone, pSP6-mTRF23, which after hybrid
selection of mRNA, a translation product was obtained that
showed both TRF and BCGFII activities (1). Both TB13 and
NC17 mAbs neutralized TRF and BCGFII activities of products
secreted by Xenopus oocytes that had been injected with mouse
TRF mRNA transcribed from plasmid pSP6K-mTRF23 (17). The
primary sequence of TRF deduced from the cDNA revealed a
novel interleukin-type molecule consisting of 133 amino acids.
The putative secreted core polypeptide has a relative m.w. of
12.3 kDa that is close to that of B151-TRF (18 kDa) after glyco-
sylation. Recombinant TRF was also found to be a dimer; reduced
and alkylated recombinant TRF lost both TRF and BCGFII activi-
ties. These properties of recombinant TRF agreed with the criteria
derived from B151 cells. We determined the partial NH2-terminal
amino-acid sequence of 13-residues of immunoaffinity-purified
recombinant TRF and B151-TRF, and found that they were nearly
identical (17). A single amino-acid sequence of each sample
obtained beginning from methionine was identical to that pre-
dicted from our cDNA, supporting the notion that secreted TRF
polypeptide consists of 113 amino acids.
Although TRF was initially believed to be principally active
on B cells, recombinant TRF was shown to increase the expres-
sion of IL-2 receptor on antigen-stimulated thymocytes, inducing
them into cytotoxic T lymphocytes (CTL) in the presence of
IL-2. TRF also induced the terminal differentiation of hematopoi-
etic progenitor cells into eosinophils, besides the activities on
activated B cells (17). As TRF was the fifth interleukin activ-
ity for which the primary structure had been determined, we
proposed that TRF and BCGFII be called interleukin-5 (IL-5)
(1). The molecular cloning of cDNA encoding both murine
and human IL-5 convincingly demonstrated that a single mole-
cule was responsible for both TRF and BCGFII activities. How-
ever, in humans, the major target cells for IL-5 are eosinophil
myeloid progenitors and mature eosinophils. Human periph-
eral blood B cells do not respond to human IL-5 by differ-
entiation to Ig-secreting cells. Consequently, the human B cell
growth and differentiation interleukins for peripheral blood B
cells appeared to be IL-2, IL-4, and IL-6 (18, 19). Subsequently,
as time progressed, several new cytokine molecules would be
described that influence B cells in addition to these first three
discovered.
Studies on IL-5 have provided strong evidence that a single
lymphokine exerts a variety of activities on diverse target cells.
Together with similar properties of IL-4, these results helped
many immunologists escape earlier beliefs that one lymphokine
is required for each activity and that growth factor activity and
differentiation factor activity are necessarily different molecular
entities.
I focused on the historical perspective of the discovery of T
cell derived IL-5 that promoted B cell growth or differentiation.
Around the same time, largely between 1985 and 1987, there were
parallel efforts by a number of groups working on eosinophil dif-
ferentiation [e.g., Ref. (20)] and T cell factors that enhanced IgA
production [e.g., Ref. (21)] that ultimately also led to purification
and identification of IL-5.
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